[go: up one dir, main page]

WO2010111633A3 - Antibody composition with altered fab sialylation - Google Patents

Antibody composition with altered fab sialylation Download PDF

Info

Publication number
WO2010111633A3
WO2010111633A3 PCT/US2010/028889 US2010028889W WO2010111633A3 WO 2010111633 A3 WO2010111633 A3 WO 2010111633A3 US 2010028889 W US2010028889 W US 2010028889W WO 2010111633 A3 WO2010111633 A3 WO 2010111633A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
population
antibody preparation
sialylation
antibody composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/028889
Other languages
French (fr)
Other versions
WO2010111633A2 (en
Inventor
Fabian Kasermann
Monika Ruegsegger
Sylvia Miescher
Keith Elkon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2012502300A priority Critical patent/JP6008740B2/en
Priority to EP10723414A priority patent/EP2411409A2/en
Priority to CN201080013511.7A priority patent/CN102574910B/en
Priority to AU2010229713A priority patent/AU2010229713B2/en
Priority to US13/260,202 priority patent/US8632773B2/en
Publication of WO2010111633A2 publication Critical patent/WO2010111633A2/en
Publication of WO2010111633A3 publication Critical patent/WO2010111633A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

The present invention relates to a population of antibodies enriched from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. Furthermore, the present invention relates to a method of enriching a population of antibodies from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. The present invention also relates to the population of antibodies of the invention for use in medicine, a pharmaceutical composition comprising the populations of antibodies of the invention and the use of the population of antibodies of the invention in the prevention and/or treatment of atherosclerosis, cancer and infections such as bacterial, viral or fungal infections.
PCT/US2010/028889 2009-03-26 2010-03-26 Antibody composition with altered fab sialylation Ceased WO2010111633A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2012502300A JP6008740B2 (en) 2009-03-26 2010-03-26 Antibody composition with altered Fab sialic acid addition
EP10723414A EP2411409A2 (en) 2009-03-26 2010-03-26 Antibody composition with altered fab sialylation
CN201080013511.7A CN102574910B (en) 2009-03-26 2010-03-26 Antibody compositions with altered Fab sialylation
AU2010229713A AU2010229713B2 (en) 2009-03-26 2010-03-26 Antibody composition with altered Fab sialylation
US13/260,202 US8632773B2 (en) 2009-03-26 2010-03-26 Antibody composition with altered Fab sialylation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09004358A EP2233499A1 (en) 2009-03-26 2009-03-26 Antibody composition with altered Fab sialylation
EP09004358.9 2009-03-26

Publications (2)

Publication Number Publication Date
WO2010111633A2 WO2010111633A2 (en) 2010-09-30
WO2010111633A3 true WO2010111633A3 (en) 2011-01-06

Family

ID=40756450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/028889 Ceased WO2010111633A2 (en) 2009-03-26 2010-03-26 Antibody composition with altered fab sialylation

Country Status (6)

Country Link
US (1) US8632773B2 (en)
EP (2) EP2233499A1 (en)
JP (1) JP6008740B2 (en)
CN (1) CN102574910B (en)
AU (1) AU2010229713B2 (en)
WO (1) WO2010111633A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527850A (en) * 2010-05-07 2013-07-04 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト Antibody composition obtained by fractionation of plasma immunoglobulin affinity chromatography on elderberry affinity column
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
CA2848510A1 (en) * 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
AU2014249290B2 (en) 2013-03-11 2018-11-22 Genzyme Corporation Hyperglycosylated binding polypeptides
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
ES2708759T3 (en) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedures for the treatment of neurodegeneration
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (en) * 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SG10201808158UA (en) 2014-03-19 2018-10-30 Genzyme Corp Site-specific glycoengineering of targeting moieties
PL3204425T3 (en) 2014-10-09 2021-03-08 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
WO2022187581A1 (en) 2021-03-04 2022-09-09 Children's Hospital Medical Center Modulation of antibody function via sialic acid modification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016455A2 (en) * 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
WO2007055916A2 (en) * 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
DK0764658T3 (en) * 1995-09-22 2002-04-22 Zlb Bioplasma Ag Process for producing immunoglobulins from fractions generated by fractionation of human blood plasma
US20040101909A1 (en) * 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
CA2614046C (en) 2005-06-30 2018-05-15 Centocor, Inc. Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ572379A (en) 2006-04-05 2012-06-29 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2091969A4 (en) 2006-10-27 2010-05-12 Univ Rockefeller POLYPEPTIDES HAVING REDUCED INCREASED ANTIINFLAMMATORY AND CYTOTOXIC PROPERTIES AND RELATED METHODS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016455A2 (en) * 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
WO2007055916A2 (en) * 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Sambucus Nigra Lectin (SNA, EBL)", 9 May 2001 (2001-05-09), pages 1, XP002602847, Retrieved from the Internet <URL:http://web.archive.org/web/20010509232352/http://vectorlabs.com/Lectins/LSNA.html> [retrieved on 20100927] *
DALZIEL M ET AL: "Lectin analysis of human immunoglobulin G N-glycan sialylation", GLYCOCONJUGATE JOURNAL, CHAPMAN & HALL, GB LNKD- DOI:10.1023/A:1007183915921, vol. 16, no. 12, 1 December 1999 (1999-12-01), pages 801 - 807, XP002575135, ISSN: 0282-0080, [retrieved on 20041028] *
JACQUEMIN M ET AL: "VARIABLE REGION HEAVY CHAIN GLYCOSYLATION DETERMINES THE ANTICOAGULANT ACTIVITY OF A FACTOR VIII ANTIBODY", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB LNKD- DOI:10.1111/J.1538-7836.2006.01900.X, vol. 4, no. 5, 1 May 2006 (2006-05-01), pages 1047 - 1055, XP009075545, ISSN: 1538-7933 *
JEFFERIS ROY: "Glycosylation as a strategy to improve antibody-based therapeutics", NATURE REVIEWS. DRUG DISCOVERY MAR 2009 LNKD- PUBMED:19247305,, vol. 8, no. 3, 1 March 2009 (2009-03-01), pages 226 - 234, XP002600969 *
KATO M ET AL: "ACTIVITY ENHANCEMENT OF A LUNG CANCER-ASSOCIATED HUMAN MONOCLONAL ANTIBODY HB4C5 BY N-DEGLYCODYLATION", HUMAN ANTIBODIES AND HYBRIDOMAS, XX, XX, vol. 4, no. 1, 1 January 1993 (1993-01-01), pages 9 - 14, XP008041607 *
KHURANA S ET AL: "THE VARIABLE DOMAIN GLYCOSYLATION IN A MONOCLONAL ANTIBODY SPECIFIC TO GNRH MODULATES ANTIGEN BINDING", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1006/BBRC.1997.5929, vol. 234, no. 2, 1 January 1997 (1997-01-01), pages 465 - 469, XP008041466, ISSN: 0006-291X *
KINOSHITA N ET AL: "Glycosylation at the Fab protion of myeloma immunoglobulin G and increased fucosylated biantennary sugar chains: structural analysis by high-performance liquid chromatography and antibody-lectin enzyme immunoassay using Lens culinaris agglutinin", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 51, 1 November 1991 (1991-11-01), pages 5888 - 5892, XP002539299, ISSN: 0008-5472 *
MILLWARD ET AL: "Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB LNKD- DOI:10.1016/J.BIOLOGICALS.2007.05.003, vol. 36, no. 1, 1 January 2008 (2008-01-01), pages 41 - 47, XP022433811, ISSN: 1045-1056 *
SEITE J F ET AL: "What is the contents of the magic draft IVIg?", AUTOIMMUNITY REVIEWS, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.AUTREV.2008.04.012, vol. 7, no. 6, 1 June 2008 (2008-06-01), pages 435 - 439, XP022732400, ISSN: 1568-9972, [retrieved on 20080502] *

Also Published As

Publication number Publication date
CN102574910B (en) 2019-09-20
CN102574910A (en) 2012-07-11
US20120009189A1 (en) 2012-01-12
AU2010229713B2 (en) 2015-07-02
EP2233499A1 (en) 2010-09-29
WO2010111633A2 (en) 2010-09-30
JP6008740B2 (en) 2016-10-19
JP2012522008A (en) 2012-09-20
AU2010229713A1 (en) 2011-10-20
US8632773B2 (en) 2014-01-21
EP2411409A2 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
WO2010111633A3 (en) Antibody composition with altered fab sialylation
HK1206755A1 (en) Low acidic species compositions and methods for producing and using the same
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
WO2009092383A3 (en) Products and methods to prevent infection
MX2012002458A (en) Humanized anti-cdcp1 antibodies.
MX358224B (en) Pharmaceutical composition for treatment and/or prevention of liver cancer.
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
MX2019004482A (en) Method for preparing an enriched igg composition from plasma.
WO2008033966A3 (en) Alphavirus replicon particles matched to protein antigens as immunological adjuvants
MX2013001613A (en) Methods and compositions for preventing a condition.
WO2013092983A3 (en) Enzymatic conjugation of polypeptides
WO2011008495A3 (en) Arginase formulations and methods
HK1206756A1 (en) Modulated lysine variant species compositions and methods for producing and using the same
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2012174158A3 (en) Administration of benzodiazepine
WO2007095288A3 (en) Methionine-containing protein or peptide compositions and methods of making and using
MY158712A (en) Therapies for preventnig or suppressing clostridium difficile infection
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
WO2012003470A3 (en) Antibody formulations
WO2012023051A3 (en) Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
PH12013500143A1 (en) A method of treating alzheimer`s disease
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
PH12012501743A1 (en) Antigen binding proteins specific for serum amyloid p component

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080013511.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10723414

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012502300

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13260202

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010229713

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010229713

Country of ref document: AU

Date of ref document: 20100326

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010723414

Country of ref document: EP